SeaSpine (SPNE) PT Set at $19.00 by HC Wainwright

Share on StockTwits

SeaSpine (NASDAQ:SPNE) received a $19.00 target price from investment analysts at HC Wainwright in a research report issued on Thursday, The Fly reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s target price indicates a potential upside of 9.51% from the stock’s current price.

Several other research analysts have also issued reports on SPNE. BidaskClub upgraded shares of SeaSpine from a “hold” rating to a “buy” rating in a research note on Saturday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price target on shares of SeaSpine in a research note on Monday, July 30th. Zacks Investment Research lowered shares of SeaSpine from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. LADENBURG THALM/SH SH set a $23.00 price target on shares of SeaSpine and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Finally, ValuEngine upgraded shares of SeaSpine from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $20.17.

Shares of NASDAQ SPNE opened at $17.35 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.91 and a quick ratio of 1.48. SeaSpine has a 12 month low of $8.76 and a 12 month high of $18.42. The firm has a market capitalization of $256.38 million, a price-to-earnings ratio of -6.72 and a beta of 0.19.

SeaSpine (NASDAQ:SPNE) last issued its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.12). The company had revenue of $35.83 million during the quarter, compared to the consensus estimate of $35.56 million. SeaSpine had a negative return on equity of 30.81% and a negative net margin of 22.60%. Equities research analysts expect that SeaSpine will post -1.94 EPS for the current year.

In related news, Director John B. Henneman III sold 4,564 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $14.72, for a total transaction of $67,182.08. Following the sale, the director now directly owns 60,144 shares of the company’s stock, valued at approximately $885,319.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John B. Henneman III sold 3,407 shares of the stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $14.65, for a total transaction of $49,912.55. Following the sale, the director now directly owns 60,144 shares in the company, valued at $881,109.60. The disclosure for this sale can be found here. 13.54% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers purchased a new stake in SeaSpine during the 2nd quarter valued at about $134,000. Northern Trust Corp grew its position in SeaSpine by 35.3% during the 1st quarter. Northern Trust Corp now owns 35,512 shares of the medical equipment provider’s stock valued at $360,000 after purchasing an additional 9,271 shares during the last quarter. Bank of New York Mellon Corp grew its position in SeaSpine by 261.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,185 shares of the medical equipment provider’s stock valued at $470,000 after purchasing an additional 26,895 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in SeaSpine by 99.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 46,267 shares of the medical equipment provider’s stock valued at $584,000 after purchasing an additional 23,090 shares during the last quarter. Finally, EAM Investors LLC purchased a new stake in SeaSpine during the 3rd quarter valued at about $850,000. 52.97% of the stock is currently owned by institutional investors.

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.

See Also: Growth Stocks, What They Are, What They Are Not

The Fly

Analyst Recommendations for SeaSpine (NASDAQ:SPNE)

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

CASI Pharmaceuticals  Announces Quarterly  Earnings Results, Misses Estimates By $0.06 EPS
CASI Pharmaceuticals Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS
Graeme Liebelt Acquires 30,075 Shares of Amcor Limited  Stock
Graeme Liebelt Acquires 30,075 Shares of Amcor Limited Stock
Insider Buying: Koppers Holdings Inc.  Insider Buys $440,220.00 in Stock
Insider Buying: Koppers Holdings Inc. Insider Buys $440,220.00 in Stock
Cedar Capital LLC Increases Position in Palo Alto Networks Inc
Cedar Capital LLC Increases Position in Palo Alto Networks Inc
Azul  Lifted to Hold at Zacks Investment Research
Azul Lifted to Hold at Zacks Investment Research
Zacks Investment Research Reiterates Hold Rating for State Street
Zacks Investment Research Reiterates Hold Rating for State Street


Leave a Reply

© 2006-2018 Ticker Report